Clinical TrialCompleted

A Study to Evaluate the Efficacy and Safety of Esketamine Combined With Oral Antidepressants in the Treatment of Major Depressive Disorder With Suicidal Ideation

Phase 4 randomized parallel-group trial of esketamine (0.25 mg/kg) vs midazolam (0.02 mg/kg) as add-on to oral antidepressants in adolescent and adult patients with MDD and suicidal ideation. Four arms (adolescent/adult × esketamine/midazolam), 25 per arm, 100 total. Primary outcome: Columbia Suicide Severity Rating Scale. Sponsor: Affiliated Brain Hospital of Guangzhou Medical University, China.

Target Enrollment
100 participants
Study Type
Phase IV interventional
Design
Randomized, double Blind

Study Details

  • Status
    Completed
  • Phase
    Phase IV
  • Type
    interventional
  • Design
    Randomizeddouble Blind
  • Target Enrollment100 participants
  • Timeline
    Start: 2021-01-01

Related Publications

Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial

Published
Authors
Lan, X-F., Wang, C-Y., Zhang, F., Liu, H., Mai, S., Ning, Y-P., Zhou, Y-L., Hu, Z., Li, W., Ye, Y.

Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial

Published
Authors
Zhou, Y., Lan, X-F., Wang, C., Zhang, F., Liu, H., Chao, Z., Ning, Y-P., Fu, L., Hu, Z., Li, W., Ye, Y.

Your Library